Cargando…
Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis
BACKGROUND: Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily clinical practice, s...
Autores principales: | Kanbayashi, Yuko, Shimizu, Mayumi, Ishizuka, Yuichi, Sawa, Shohei, Yabe, Katsushige, Uchida, Mayako |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733844/ https://www.ncbi.nlm.nih.gov/pubmed/36490241 http://dx.doi.org/10.1371/journal.pone.0278823 |
Ejemplares similares
-
A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy
por: Webster, Lynn R, et al.
Publicado: (2020) -
Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
por: BouSaba, Joelle, et al.
Publicado: (2022) -
Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
por: Osaka, Iwao, et al.
Publicado: (2019) -
Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
por: Wild, James, et al.
Publicado: (2020) -
A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients
por: Imai, Hisao, et al.
Publicado: (2022)